- Home
- NURO vs GRI Comparison
NURO vs GRI Comparison
Compare NURO & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NURO
- GRI
- Stock Information
- Founded
- NURO 1996
- GRI 2018
- Country
- NURO United States
- GRI United States
- Employees
- NURO N/A
- GRI N/A
- Industry
- NURO Medical/Dental Instruments
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- NURO Health Care
- GRI Health Care
- Exchange
- NURO Nasdaq
- GRI Nasdaq
- Market Cap
- NURO 7.6M
- GRI 6.1M
- IPO Year
- NURO N/A
- GRI N/A
- Fundamental
- Price
- NURO $4.05
- GRI $0.72
- Analyst Decision
- NURO
- GRI Strong Buy
- Analyst Count
- NURO 0
- GRI 2
- Target Price
- NURO N/A
- GRI $11.50
- AVG Volume (30 Days)
- NURO 28.9K
- GRI 182.9K
- Earning Date
- NURO 02-20-2025
- GRI 11-14-2024
- Dividend Yield
- NURO N/A
- GRI N/A
- EPS Growth
- NURO N/A
- GRI N/A
- EPS
- NURO N/A
- GRI N/A
- Revenue
- NURO $3,767,764.00
- GRI N/A
- Revenue This Year
- NURO N/A
- GRI N/A
- Revenue Next Year
- NURO N/A
- GRI N/A
- P/E Ratio
- NURO N/A
- GRI N/A
- Revenue Growth
- NURO N/A
- GRI N/A
- 52 Week Low
- NURO $2.66
- GRI $0.30
- 52 Week High
- NURO $4.73
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- NURO 54.09
- GRI 44.58
- Support Level
- NURO $3.93
- GRI $0.68
- Resistance Level
- NURO $4.13
- GRI $0.77
- Average True Range (ATR)
- NURO 0.11
- GRI 0.07
- MACD
- NURO 0.01
- GRI -0.01
- Stochastic Oscillator
- NURO 70.37
- GRI 16.44
About NURO NeuroMetrix Inc.
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.